Table 1.
Study population characteristics in total, cachectic, and non-cachectic cohorts.
| Characteristic | Total cohort | No cachexia | Cachexia | Percent with cachexia |
|---|---|---|---|---|
| N | 3180 | 2097 | 1083 | 34.06% |
| Median age at diagnosis (IQR) | 62 (55-71) | 63 (55-71) | 62 (54-71) | |
| Female (%) | 1355 (42.61%) | 929 (44.30%) | 426 (39.33%) | 31.44%‡ |
| Race (%) | ||||
| Asian or Pacific Islander | 127 (3.99%) | 82 (3.91%) | 45 (4.16%) | 35.43% |
| Black | 758 (23.84%) | 426 (20.31%) | 332 (30.66%) | 43.80% † |
| Non-Hispanic White | 1854 (58.30%) | 1332 (63.52%) | 522 (48.20%) | 28.16%‡ |
| Hispanic | 363 (11.42%) | 206 (9.82%) | 157 (14.50%) | 43.25%† |
| Other/unknown | 78 (2.45%) | 51 (2.43%) | 27 (2.49%) | 34.62% |
| Primary tumor site (%) | ||||
| Anal | 92 (2.89%) | 68 (3.24%) | 24 (2.22%) | 26.09% |
| Colorectal | 623 (19.59%) | 451 (21.51%) | 172 (15.88%) | 27.61%‡ |
| Gastroesophageal | 329 (10.35%) | 143 (6.82%) | 186 (17.17%) | 56.53%† |
| Hepatobilliary | 342 (10.75%) | 259 (12.35%) | 83 (7.66%) | 24.27%‡ |
| Pancreatic | 267 (8.40%) | 125 (5.96%) | 142 (13.11%) | 53.18%† |
| NSCLC | 1369 (43.05%) | 953 (45.45%) | 416 (38.41%) | 30.39%‡ |
| Small cell lung cancer | 158 (4.97%) | 98 (4.67%) | 60 (5.54%) | 37.97% |
| Tobacco (%) | 2267 (71.29%) | 1477 (70.43%) | 790 (72.95%) | 34.85% |
| Alcohol (%) | 1502 (47.23%) | 1005 (47.93%) | 497 (45.89%) | 33.09% |
| Charlson comorbidity index (%) | ||||
| 0 | 1034 (32.52%) | 642 (30.62%) | 392 (36.20%) | 37.91%† |
| 1 | 1049 (32.99%) | 679 (32.38%) | 370 (34.16%) | 35.27% |
| 2 | 541 (17.01%) | 366 (17.45%) | 175 (16.16%) | 32.35% |
| 3+ | 556 (17.48%) | 410 (19.55%) | 146 (13.48%) | 26.26%‡ |
| Tumor grade (%) | ||||
| 1 | 142 (7.28%) | 111 (8.42%) | 31 (4.91%) | 21.83%‡ |
| 2 | 1034 (53.03%) | 731 (55.42%) | 303 (48.02%) | 29.30%‡ |
| 3 | 739 (37.90%) | 459 (34.80%) | 280 (44.37%) | 37.89%† |
| 4 | 35 (1.79%) | 18 (1.36%) | 17 (2.69%) | 48.57%† |
| Tumor stage (%) | ||||
| 1 | 541 (17.54%) | 446 (21.86%) | 95 (9.09%) | 17.56%‡ |
| 2 | 531 (17.21%) | 394 (19.31%) | 137 (13.11%) | 25.80%‡ |
| 3 | 879 (28.49%) | 557 (27.30%) | 322 (30.81%) | 36.63%† |
| 4 | 1134 (36.76%) | 643 (31.52%) | 491 (46.99%) | 43.30%† |
Significantly increased (†) or decreased (‡) cachexia incidence within row category relative to total cohort indicated (P<0.05).
Significant (*) or non-significant (n.s.) differences of cachexia incidence between medication use groups indicated (P<0.05).